PROM1 and hepatocellular carcinoma: More importantly, CD133-directed CAR-T has been assessed in a phase 1 and phase 2 clinical study (NCT02541370) (23 patients, including 14 with HCC), which showed that primary toxicity due to a decrease in the haemoglobin/platelet ratio (Grade 3) showed self-recovery within 1 week.